172 related articles for article (PubMed ID: 8560135)
1. L-dopa therapy of uremic and idiopathic restless legs syndrome: a double-blind, crossover trial.
Trenkwalder C; Stiasny K; Pollmächer T; Wetter T; Schwarz J; Kohnen R; Kazenwadel J; Krüger HP; Ramm S; Künzel M
Sleep; 1995 Oct; 18(8):681-8. PubMed ID: 8560135
[TBL] [Abstract][Full Text] [Related]
2. [Treatment of idiopathic and uremic restless legs syndrome with L-dopa--a double-blind cross-over study].
Wetter TC; Trenkwalder C; Stiasny K; Pollmächer T; Kazenwadel J; Kohnen R; Künzel M; Oertel WH
Wien Med Wochenschr; 1995; 145(17-18):525-7. PubMed ID: 8588396
[TBL] [Abstract][Full Text] [Related]
3. A controlled study of additional sr-L-dopa in L-dopa-responsive restless legs syndrome with late-night symptoms.
Collado-Seidel V; Kazenwadel J; Wetter TC; Kohnen R; Winkelmann J; Selzer R; Oertel WH; Trenkwalder C
Neurology; 1999 Jan; 52(2):285-90. PubMed ID: 9932945
[TBL] [Abstract][Full Text] [Related]
4. Acute double-blind, placebo-controlled sleep laboratory and clinical follow-up studies with a combination treatment of rr-L-dopa and sr-L-dopa in restless legs syndrome.
Saletu M; Anderer P; Högl B; Saletu-Zyhlarz G; Kunz A; Poewe W; Saletu B
J Neural Transm (Vienna); 2003 Jun; 110(6):611-26. PubMed ID: 12768357
[TBL] [Abstract][Full Text] [Related]
5. L-DOPA/carbidopa for nocturnal movement disorders in uremia.
Walker SL; Fine A; Kryger MH
Sleep; 1996 Apr; 19(3):214-8. PubMed ID: 8723378
[TBL] [Abstract][Full Text] [Related]
6. Rapid onset of action of levodopa in restless legs syndrome: a double-blind, randomized, multicenter, crossover trial.
Benes H; Kurella B; Kummer J; Kazenwadel J; Selzer R; Kohnen R
Sleep; 1999 Dec; 22(8):1073-81. PubMed ID: 10617168
[TBL] [Abstract][Full Text] [Related]
7. Treatment of idiopathic restless legs syndrome (RLS) with slow-release valproic acid compared with slow-release levodopa/benserazid.
Eisensehr I; Ehrenberg BL; Rogge Solti S; Noachtar S
J Neurol; 2004 May; 251(5):579-83. PubMed ID: 15164191
[TBL] [Abstract][Full Text] [Related]
8. Treatment of restless legs syndrome and periodic movements during sleep with L-dopa: a double-blind, controlled study.
Brodeur C; Montplaisir J; Godbout R; Marinier R
Neurology; 1988 Dec; 38(12):1845-8. PubMed ID: 3057399
[TBL] [Abstract][Full Text] [Related]
9. One-year treatment with standard and sustained-release levodopa: appropriate long-term treatment of restless legs syndrome?
Trenkwalder C; Collado Seidel V; Kazenwadel J; Wetter TC; Oertel W; Selzer R; Kohnen R
Mov Disord; 2003 Oct; 18(10):1184-9. PubMed ID: 14534925
[TBL] [Abstract][Full Text] [Related]
10. Pramipexole versus dual release levodopa in restless legs syndrome: a double blind, randomised, cross-over trial.
Bassetti CL; Bornatico F; Fuhr P; Schwander J; Kallweit U; Mathis J;
Swiss Med Wkly; 2011; 141():w13274. PubMed ID: 22101745
[TBL] [Abstract][Full Text] [Related]
11. [Therapy of idiopathic and uremic restless legs syndrome].
Trenkwalder C; Stiasny K; Oertel WH
Nervenarzt; 1996 Apr; 67(4):265-76. PubMed ID: 8684504
[TBL] [Abstract][Full Text] [Related]
12. Levodopa for idiopathic restless legs syndrome: evidence-based review.
Conti CF; de Oliveira MM; Andriolo RB; Saconato H; Atallah AN; Valbuza JS; Coin de Carvalho LB; do Prado GF
Mov Disord; 2007 Oct; 22(13):1943-51. PubMed ID: 17659645
[TBL] [Abstract][Full Text] [Related]
13. Effect of pergolide on restless legs and leg movements in sleep in uremic patients.
Pieta J; Millar T; Zacharias J; Fine A; Kryger M
Sleep; 1998 Sep; 21(6):617-22. PubMed ID: 9779521
[TBL] [Abstract][Full Text] [Related]
14. The pharmacological treatment for uremic restless legs syndrome: evidence-based review.
de Oliveira MM; Conti CF; Valbuza JS; de Carvalho LB; do Prado GF
Mov Disord; 2010 Jul; 25(10):1335-42. PubMed ID: 20544816
[TBL] [Abstract][Full Text] [Related]
15. L-Dopa improves Restless Legs Syndrome and periodic limb movements in sleep but not Attention-Deficit-Hyperactivity Disorder in a double-blind trial in children.
England SJ; Picchietti DL; Couvadelli BV; Fisher BC; Siddiqui F; Wagner ML; Hening WA; Lewin D; Winnie G; Cohen B; Walters AS
Sleep Med; 2011 May; 12(5):471-7. PubMed ID: 21463967
[TBL] [Abstract][Full Text] [Related]
16. Low-dose pramipexole in the management of restless legs syndrome. An open label trial.
Stiasny-Kolster K; Oertel WH
Neuropsychobiology; 2004; 50(1):65-70. PubMed ID: 15179023
[TBL] [Abstract][Full Text] [Related]
17. Circadian variation in neuroendocrine response to L-dopa in patients with restless legs syndrome.
Garcia-Borreguero D; Larrosa O; Granizo JJ; de la Llave Y; Hening WA
Sleep; 2004 Jun; 27(4):669-73. PubMed ID: 15283001
[TBL] [Abstract][Full Text] [Related]
18. Treatment of periodic leg movements with a dopaminergic agonist in subjects with total spinal cord lesions.
de Mello MT; Poyares DL; Tufik S
Spinal Cord; 1999 Sep; 37(9):634-7. PubMed ID: 10490854
[TBL] [Abstract][Full Text] [Related]
19. Treatment of idiopathic restless legs syndrome (RLS) with the D2-agonist cabergoline--an open clinical trial.
Stiasny K; Röbbecke J; Schüler P; Oertel WH
Sleep; 2000 May; 23(3):349-54. PubMed ID: 10811379
[TBL] [Abstract][Full Text] [Related]
20. Pergolide: treatment of choice in restless legs syndrome (RLS) and nocturnal myoclonus syndrome (NMS). A double-blind randomized crossover trial of pergolide versus L-Dopa.
Staedt J; Wassmuth F; Ziemann U; Hajak G; Rüther E; Stoppe G
J Neural Transm (Vienna); 1997; 104(4-5):461-8. PubMed ID: 9295178
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
